Company Overview
| Stock Name | 雅各臣科研製藥有限公司 |
|---|---|
| Stock Code | 02633 |
| Company Full Name | 雅各臣科研製藥有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要在香港從事開發、制造及分銷非專利藥物、品牌藥、品牌中藥及健康保健品。 |
| Listing Date | 2016-09-21 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港九龍觀塘道388號創紀之城1期1座23樓2313-18室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.jacobsonpharma.com |
| Share Registrar | |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 1.50 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 4.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 65,628,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 1.68 |
|---|---|
| First Day Open | HK$ 1.58 |
| First Day Change | 12.00% |
| First Day Volume | 107290000.0 |
| First Day Turnover | 173359000.0 |
Use of Proceeds
| Use of Proceeds | 1、約45%（或270.5百萬港元）用作收購事項； 2、約18%（或108.2百萬港元）用作有關收購、拓展、精簡或提升我們的制造廠房、房產、設施或產能的資本投資； 3、約15%（或90.2百萬港元）用作為專門非專利藥進行生物等效性臨床研究； 4、約12%（或72.1百萬港元）用作在未來五年加大我們的銷售、市場推廣及廣告宣傳力度，以提升品牌的認可度及加強我們產品及業務的品牌忠誠度； 5、約10%（或60.1百萬港元）用作營運資金及其他一般公司用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
中银国际亚洲有限公司 CE AET863
Joint Bookrunners (1)
中银国际亚洲有限公司 CE AET863
Joint Lead Managers (1)
中银国际亚洲有限公司 CE AET863
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | New Heritage Healthcare Limited | 49,998,000 HKD | — | 1.90% | — | 6 months | 2017-03-21 |
| 2 | 香港荣华药业集团有限公司 | 79,998,000 HKD | — | 3.00% | — | 6 months | 2017-03-21 |
Directors & Management
| Chairman | 岑廣業 |
|---|---|
| Company Secretary | 余振球 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 岑廣業(60.59%);云南白藥控股有限公司(10.34%);劉榮雄及家族成員(8.11%) |
|---|
